QuidelOrtho (QDEL) to Release Earnings on Tuesday

QuidelOrtho (NASDAQ:QDEL) is expected to be announcing its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.07 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Thursday, November 7th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.55. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. The business had revenue of $727.00 million during the quarter, compared to analyst estimates of $642.16 million. During the same quarter in the previous year, the firm earned $0.90 EPS. The company’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

QuidelOrtho Stock Performance

NASDAQ QDEL opened at $42.89 on Monday. The company’s 50 day simple moving average is $43.21 and its two-hundred day simple moving average is $42.29. The stock has a market capitalization of $2.88 billion, a PE ratio of -1.54 and a beta of 0.08. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.38 and a quick ratio of 0.81. QuidelOrtho has a 1 year low of $29.74 and a 1 year high of $69.83.

Analyst Upgrades and Downgrades

QDEL has been the subject of a number of recent research reports. Citigroup raised QuidelOrtho from a “neutral” rating to a “buy” rating and raised their price objective for the company from $44.00 to $50.00 in a research note on Wednesday, December 11th. StockNews.com upgraded QuidelOrtho from a “hold” rating to a “buy” rating in a report on Friday. Jefferies Financial Group assumed coverage on QuidelOrtho in a report on Tuesday, December 10th. They issued a “hold” rating and a $43.00 price objective for the company. Finally, William Blair reissued a “market perform” rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $53.43.

Insider Buying and Selling

In other QuidelOrtho news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $35.31, for a total transaction of $291,667,061.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brian J. Blaser bought 6,033 shares of QuidelOrtho stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average price of $41.42 per share, for a total transaction of $249,886.86. Following the completion of the acquisition, the chief executive officer now owns 6,033 shares in the company, valued at approximately $249,886.86. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.00% of the stock is currently owned by insiders.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.